Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).

American journal of hematology

Voorhees PM, Suman VJ, Tuchman SA, Laubach JP, Hassoun H, Efebera YA, Mulkey F, Bova-Solem M, Santo K, Carlisle D, McCarthy PL, Richardson PG.
PMID: 34559902
Am J Hematol. 2021 Dec 01;96(12):1595-1603. doi: 10.1002/ajh.26361. Epub 2021 Oct 06.

Preclinical studies have demonstrated activity of the oral proteasome inhibitor (PI) ixazomib (IXA) in bortezomib-resistant multiple myeloma (MM) and synergy with immunomodulatory drugs. We therefore conducted a phase I/II study to establish the safety and preliminary efficacy of IXA...

Cite
Voorhees PM, Suman VJ, Tuchman SA, et al. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol. 2021;96(12):1595-1603doi: 10.1002/ajh.26361.
Voorhees, P. M., Suman, V. J., Tuchman, S. A., Laubach, J. P., Hassoun, H., Efebera, Y. A., Mulkey, F., Bova-Solem, M., Santo, K., Carlisle, D., McCarthy, P. L., & Richardson, P. G. (2021). A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). American journal of hematology, 96(12), 1595-1603. https://doi.org/10.1002/ajh.26361
Voorhees, Peter M, et al. "A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)." American journal of hematology vol. 96,12 (2021): 1595-1603. doi: https://doi.org/10.1002/ajh.26361
Voorhees PM, Suman VJ, Tuchman SA, Laubach JP, Hassoun H, Efebera YA, Mulkey F, Bova-Solem M, Santo K, Carlisle D, McCarthy PL, Richardson PG. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol. 2021 Dec 01;96(12):1595-1603. doi: 10.1002/ajh.26361. Epub 2021 Oct 06. PMID: 34559902; PMCID: PMC8713771.
Copy Download .nbib Format: NLM
Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia.

Haematologica

Papaioannou D, Ozer HG, Nicolet D, Urs AP, Herold T, Mrózek K, Batcha AMN, Metzeler KH, Yilmaz AS, Volinia S, Bill M, Kohlschmidt J, Pietrzak M, Walker CJ, Carroll AJ, Braess J, Powell BL, Eisfeld AK, Uy GL, Wang ES, Kolitz JE, Stone RM, Hiddemann W, Byrd JC, Bloomfield CD, Garzon R.
PMID: 34261293
Haematologica. 2021 Jul 15; doi: 10.3324/haematol.2021.266643. Epub 2021 Jul 15.

Expression levels of long non-coding RNAs (lncRNAs) have been shown to associate with clinical outcome of patients with cytogenetically normal acute myeloid leukemia (CN-AML). However, the frequency and clinical significance of genetic variants in the nucleotide sequences of lncRNAs...

Cite
Papaioannou D, Ozer HG, Nicolet D, et al. Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. Haematologica. 2021;doi: 10.3324/haematol.2021.266643.
Papaioannou, D., Ozer, H. G., Nicolet, D., Urs, A. P., Herold, T., Mrózek, K., Batcha, A. M. N., Metzeler, K. H., Yilmaz, A. S., Volinia, S., Bill, M., Kohlschmidt, J., Pietrzak, M., Walker, C. J., Carroll, A. J., Braess, J., Powell, B. L., Eisfeld, A. K., Uy, G. L., Wang, E. S., Kolitz, J. E., Stone, R. M., Hiddemann, W., Byrd, J. C., Bloomfield, C. D., & Garzon, R. (2021). Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. Haematologica, . https://doi.org/10.3324/haematol.2021.266643
Papaioannou, Dimitrios, et al. "Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia." Haematologica vol. (2021). doi: https://doi.org/10.3324/haematol.2021.266643
Papaioannou D, Ozer HG, Nicolet D, Urs AP, Herold T, Mrózek K, Batcha AMN, Metzeler KH, Yilmaz AS, Volinia S, Bill M, Kohlschmidt J, Pietrzak M, Walker CJ, Carroll AJ, Braess J, Powell BL, Eisfeld AK, Uy GL, Wang ES, Kolitz JE, Stone RM, Hiddemann W, Byrd JC, Bloomfield CD, Garzon R. Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. Haematologica. 2021 Jul 15; doi: 10.3324/haematol.2021.266643. Epub 2021 Jul 15. PMID: 34261293.
Copy Download .nbib Format: NLM
Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199).

JNCI cancer spectrum

Mai PL, Miller A, Gail MH, Skates S, Lu K, Sherman ME, Ioffe OB, Rodriguez G, Cohn DE, Boggess J, Rutherford T, Kauff ND, Rader JS, Phillips KA, DiSilvestro PA, Olawaiye AB, Ridgway MR, Greene MH, Piedmonte M, Walker JL.
PMID: 32337492
JNCI Cancer Spectr. 2019 Oct 10;4(1):pkz075. doi: 10.1093/jncics/pkz075. eCollection 2020 Feb.

BACKGROUND: Risk-reducing salpingo-oophorectomy (RRSO) has been associated with approximately 50% breast cancer risk reduction among women with a pathogenic variant in METHODS: We estimated incidence rates of breast cancer and all cancers combined during 5 years of follow-up among...

Cite
Mai PL, Miller A, Gail MH, et al. Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). JNCI Cancer Spectr. 2019;4(1):pkz075doi: 10.1093/jncics/pkz075.
Mai, P. L., Miller, A., Gail, M. H., Skates, S., Lu, K., Sherman, M. E., Ioffe, O. B., Rodriguez, G., Cohn, D. E., Boggess, J., Rutherford, T., Kauff, N. D., Rader, J. S., Phillips, K. A., DiSilvestro, P. A., Olawaiye, A. B., Ridgway, M. R., Greene, M. H., Piedmonte, M., & Walker, J. L. (2020). Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). JNCI cancer spectrum, 4(1), pkz075. https://doi.org/10.1093/jncics/pkz075
Mai, Phuong L, et al. "Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199)." JNCI cancer spectrum vol. 4,1 (2020): pkz075. doi: https://doi.org/10.1093/jncics/pkz075
Mai PL, Miller A, Gail MH, Skates S, Lu K, Sherman ME, Ioffe OB, Rodriguez G, Cohn DE, Boggess J, Rutherford T, Kauff ND, Rader JS, Phillips KA, DiSilvestro PA, Olawaiye AB, Ridgway MR, Greene MH, Piedmonte M, Walker JL. Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). JNCI Cancer Spectr. 2019 Oct 10;4(1):pkz075. doi: 10.1093/jncics/pkz075. eCollection 2020 Feb. PMID: 32337492; PMCID: PMC7050151.
Copy Download .nbib Format: NLM
Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia.

Haematologica

Papaioannou D, Ozer HG, Nicolet D, Urs AP, Herold T, Mrózek K, Batcha AMN, Metzeler KH, Yilmaz AS, Volinia S, Bill M, Kohlschmidt J, Pietrzak M, Walker CJ, Carroll AJ, Braess J, Powell BL, Eisfeld AK, Uy GL, Wang ES, Kolitz JE, Stone RM, Hiddemann W, Byrd JC, Bloomfield CD, Garzon R.
PMID: 34261293
Haematologica. 2021 Jul 15; doi: 10.3324/haematol.2021.266643. Epub 2021 Jul 15.

Expression levels of long non-coding RNAs (lncRNAs) have been shown to associate with clinical outcome of patients with cytogenetically normal acute myeloid leukemia (CN-AML). However, the frequency and clinical significance of genetic variants in the nucleotide sequences of lncRNAs...

Cite
Papaioannou D, Ozer HG, Nicolet D, et al. Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. Haematologica. 2021;doi: 10.3324/haematol.2021.266643.
Papaioannou, D., Ozer, H. G., Nicolet, D., Urs, A. P., Herold, T., Mrózek, K., Batcha, A. M. N., Metzeler, K. H., Yilmaz, A. S., Volinia, S., Bill, M., Kohlschmidt, J., Pietrzak, M., Walker, C. J., Carroll, A. J., Braess, J., Powell, B. L., Eisfeld, A. K., Uy, G. L., Wang, E. S., Kolitz, J. E., Stone, R. M., Hiddemann, W., Byrd, J. C., Bloomfield, C. D., & Garzon, R. (2021). Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. Haematologica, . https://doi.org/10.3324/haematol.2021.266643
Papaioannou, Dimitrios, et al. "Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia." Haematologica vol. (2021). doi: https://doi.org/10.3324/haematol.2021.266643
Papaioannou D, Ozer HG, Nicolet D, Urs AP, Herold T, Mrózek K, Batcha AMN, Metzeler KH, Yilmaz AS, Volinia S, Bill M, Kohlschmidt J, Pietrzak M, Walker CJ, Carroll AJ, Braess J, Powell BL, Eisfeld AK, Uy GL, Wang ES, Kolitz JE, Stone RM, Hiddemann W, Byrd JC, Bloomfield CD, Garzon R. Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. Haematologica. 2021 Jul 15; doi: 10.3324/haematol.2021.266643. Epub 2021 Jul 15. PMID: 34261293.
Copy Download .nbib Format: NLM
Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer.

Oncotarget

Tsuji T, Eng KH, Matsuzaki J, Battaglia S, Szender JB, Miliotto A, Gnjatic S, Bshara W, Morrison CD, Lele S, Emerson RO, Wang J, Liu S, Robins H, Lugade AA, Odunsi K.
PMID: 32676168
Oncotarget. 2020 Jul 07;11(27):2669-2683. doi: 10.18632/oncotarget.27666. eCollection 2020 Jul 07.

CD8

Cite
Tsuji T, Eng KH, Matsuzaki J, et al. Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer. Oncotarget. 2020;11(27):2669-2683doi: 10.18632/oncotarget.27666.
Tsuji, T., Eng, K. H., Matsuzaki, J., Battaglia, S., Szender, J. B., Miliotto, A., Gnjatic, S., Bshara, W., Morrison, C. D., Lele, S., Emerson, R. O., Wang, J., Liu, S., Robins, H., Lugade, A. A., & Odunsi, K. (2020). Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer. Oncotarget, 11(27), 2669-2683. https://doi.org/10.18632/oncotarget.27666
Tsuji, Takemasa, et al. "Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer." Oncotarget vol. 11,27 (2020): 2669-2683. doi: https://doi.org/10.18632/oncotarget.27666
Tsuji T, Eng KH, Matsuzaki J, Battaglia S, Szender JB, Miliotto A, Gnjatic S, Bshara W, Morrison CD, Lele S, Emerson RO, Wang J, Liu S, Robins H, Lugade AA, Odunsi K. Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer. Oncotarget. 2020 Jul 07;11(27):2669-2683. doi: 10.18632/oncotarget.27666. eCollection 2020 Jul 07. PMID: 32676168; PMCID: PMC7343634.
Copy Download .nbib Format: NLM
Transmission of X-linked Ovarian Cancer: Characterization and Implications.

Diagnostics (Basel, Switzerland)

Etter JL, Moysich K, Kohli S, Lele S, Odunsi K, Eng KH.
PMID: 32046210
Diagnostics (Basel). 2020 Feb 07;10(2). doi: 10.3390/diagnostics10020090.

We recently reported evidence that a strong, BRCA-independent locus on the X-chromosome may contribute to ovarian cancer predisposition in families ascertained from the Familial Ovarian Cancer Registry (Buffalo, NY, USA). While it has been estimated that approximately 20% of...

Cite
Etter JL, Moysich K, Kohli S, et al. Transmission of X-linked Ovarian Cancer: Characterization and Implications. Diagnostics (Basel). 2020;10(2)doi: 10.3390/diagnostics10020090.
Etter, J. L., Moysich, K., Kohli, S., Lele, S., Odunsi, K., & Eng, K. H. (2020). Transmission of X-linked Ovarian Cancer: Characterization and Implications. Diagnostics (Basel, Switzerland), 10(2), . https://doi.org/10.3390/diagnostics10020090
Etter, John Lewis, et al. "Transmission of X-linked Ovarian Cancer: Characterization and Implications." Diagnostics (Basel, Switzerland) vol. 10,2 (2020). doi: https://doi.org/10.3390/diagnostics10020090
Etter JL, Moysich K, Kohli S, Lele S, Odunsi K, Eng KH. Transmission of X-linked Ovarian Cancer: Characterization and Implications. Diagnostics (Basel). 2020 Feb 07;10(2). doi: 10.3390/diagnostics10020090. PMID: 32046210; PMCID: PMC7167857.
Copy Download .nbib Format: NLM
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).

American journal of hematology

Voorhees PM, Suman VJ, Tuchman SA, Laubach JP, Hassoun H, Efebera YA, Mulkey F, Bova-Solem M, Santo K, Carlisle D, McCarthy PL, Richardson PG.
PMID: 34559902
Am J Hematol. 2021 Dec 01;96(12):1595-1603. doi: 10.1002/ajh.26361. Epub 2021 Oct 06.

Preclinical studies have demonstrated activity of the oral proteasome inhibitor (PI) ixazomib (IXA) in bortezomib-resistant multiple myeloma (MM) and synergy with immunomodulatory drugs. We therefore conducted a phase I/II study to establish the safety and preliminary efficacy of IXA...

Cite
Voorhees PM, Suman VJ, Tuchman SA, et al. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol. 2021;96(12):1595-1603doi: 10.1002/ajh.26361.
Voorhees, P. M., Suman, V. J., Tuchman, S. A., Laubach, J. P., Hassoun, H., Efebera, Y. A., Mulkey, F., Bova-Solem, M., Santo, K., Carlisle, D., McCarthy, P. L., & Richardson, P. G. (2021). A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). American journal of hematology, 96(12), 1595-1603. https://doi.org/10.1002/ajh.26361
Voorhees, Peter M, et al. "A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)." American journal of hematology vol. 96,12 (2021): 1595-1603. doi: https://doi.org/10.1002/ajh.26361
Voorhees PM, Suman VJ, Tuchman SA, Laubach JP, Hassoun H, Efebera YA, Mulkey F, Bova-Solem M, Santo K, Carlisle D, McCarthy PL, Richardson PG. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol. 2021 Dec 01;96(12):1595-1603. doi: 10.1002/ajh.26361. Epub 2021 Oct 06. PMID: 34559902; PMCID: PMC8713771.
Copy Download .nbib Format: NLM
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).

American journal of hematology

Voorhees PM, Suman VJ, Tuchman SA, Laubach JP, Hassoun H, Efebera YA, Mulkey F, Bova-Solem M, Santo K, Carlisle D, McCarthy PL, Richardson PG.
PMID: 34559902
Am J Hematol. 2021 Dec 01;96(12):1595-1603. doi: 10.1002/ajh.26361. Epub 2021 Oct 06.

Preclinical studies have demonstrated activity of the oral proteasome inhibitor (PI) ixazomib (IXA) in bortezomib-resistant multiple myeloma (MM) and synergy with immunomodulatory drugs. We therefore conducted a phase I/II study to establish the safety and preliminary efficacy of IXA...

Cite
Voorhees PM, Suman VJ, Tuchman SA, et al. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol. 2021;96(12):1595-1603doi: 10.1002/ajh.26361.
Voorhees, P. M., Suman, V. J., Tuchman, S. A., Laubach, J. P., Hassoun, H., Efebera, Y. A., Mulkey, F., Bova-Solem, M., Santo, K., Carlisle, D., McCarthy, P. L., & Richardson, P. G. (2021). A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). American journal of hematology, 96(12), 1595-1603. https://doi.org/10.1002/ajh.26361
Voorhees, Peter M, et al. "A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)." American journal of hematology vol. 96,12 (2021): 1595-1603. doi: https://doi.org/10.1002/ajh.26361
Voorhees PM, Suman VJ, Tuchman SA, Laubach JP, Hassoun H, Efebera YA, Mulkey F, Bova-Solem M, Santo K, Carlisle D, McCarthy PL, Richardson PG. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol. 2021 Dec 01;96(12):1595-1603. doi: 10.1002/ajh.26361. Epub 2021 Oct 06. PMID: 34559902.
Copy Download .nbib Format: NLM
Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer.

JAMA oncology

Mayadev JS, Enserro D, Lin YG, Da Silva DM, Lankes HA, Aghajanian C, Ghamande S, Moore KN, Kennedy VA, Fracasso PM, Schilder RJ.
PMID: 31774464
JAMA Oncol. 2020 Jan 01;6(1):92-99. doi: 10.1001/jamaoncol.2019.3857.

IMPORTANCE: Despite standard chemoradiotherapy (CRT), most women with lymph node (LN)-positive cervical cancer experience disease recurrence. Immunotherapy is being investigated in the up-front treatment setting.OBJECTIVES: To assess the safety of sequential immunotherapy after CRT and to investigate human papillomavirus...

Cite
Mayadev JS, Enserro D, Lin YG, et al. Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. JAMA Oncol. 2020;6(1):92-99doi: 10.1001/jamaoncol.2019.3857.
Mayadev, J. S., Enserro, D., Lin, Y. G., Da Silva, D. M., Lankes, H. A., Aghajanian, C., Ghamande, S., Moore, K. N., Kennedy, V. A., Fracasso, P. M., & Schilder, R. J. (2020). Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. JAMA oncology, 6(1), 92-99. https://doi.org/10.1001/jamaoncol.2019.3857
Mayadev, Jyoti S, et al. "Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer." JAMA oncology vol. 6,1 (2020): 92-99. doi: https://doi.org/10.1001/jamaoncol.2019.3857
Mayadev JS, Enserro D, Lin YG, Da Silva DM, Lankes HA, Aghajanian C, Ghamande S, Moore KN, Kennedy VA, Fracasso PM, Schilder RJ. Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. JAMA Oncol. 2020 Jan 01;6(1):92-99. doi: 10.1001/jamaoncol.2019.3857. PMID: 31774464; PMCID: PMC6902184.
Copy Download .nbib Format: NLM
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).

American journal of hematology

Voorhees PM, Suman VJ, Tuchman SA, Laubach JP, Hassoun H, Efebera YA, Mulkey F, Bova-Solem M, Santo K, Carlisle D, McCarthy PL, Richardson PG.
PMID: 34559902
Am J Hematol. 2021 Dec 01;96(12):1595-1603. doi: 10.1002/ajh.26361. Epub 2021 Oct 06.

Preclinical studies have demonstrated activity of the oral proteasome inhibitor (PI) ixazomib (IXA) in bortezomib-resistant multiple myeloma (MM) and synergy with immunomodulatory drugs. We therefore conducted a phase I/II study to establish the safety and preliminary efficacy of IXA...

Cite
Voorhees PM, Suman VJ, Tuchman SA, et al. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol. 2021;96(12):1595-1603doi: 10.1002/ajh.26361.
Voorhees, P. M., Suman, V. J., Tuchman, S. A., Laubach, J. P., Hassoun, H., Efebera, Y. A., Mulkey, F., Bova-Solem, M., Santo, K., Carlisle, D., McCarthy, P. L., & Richardson, P. G. (2021). A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). American journal of hematology, 96(12), 1595-1603. https://doi.org/10.1002/ajh.26361
Voorhees, Peter M, et al. "A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)." American journal of hematology vol. 96,12 (2021): 1595-1603. doi: https://doi.org/10.1002/ajh.26361
Voorhees PM, Suman VJ, Tuchman SA, Laubach JP, Hassoun H, Efebera YA, Mulkey F, Bova-Solem M, Santo K, Carlisle D, McCarthy PL, Richardson PG. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol. 2021 Dec 01;96(12):1595-1603. doi: 10.1002/ajh.26361. Epub 2021 Oct 06. PMID: 34559902.
Copy Download .nbib Format: NLM
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).

Gynecologic oncology reports

Santin AD, Filiaci V, Bellone S, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Frumovitz M, Khleif SN, Huh WK, Birrer MJ.
PMID: 31934607
Gynecol Oncol Rep. 2020 Jan 02;31:100532. doi: 10.1016/j.gore.2019.100532. eCollection 2020 Feb.

PURPOSE: NRG Oncology conducted a phase II trial to assess the antitumor activity and tolerability of copanlisib, a selective inhibitor of PIK3CA, in persistent or recurrent endometrial carcinoma harboring hotspot PIK3CA mutations.PATIENTS AND METHODS: Eligible patients had endometrial cancer...

Cite
Santin AD, Filiaci V, Bellone S, et al. Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). Gynecol Oncol Rep. 2020;31:100532doi: 10.1016/j.gore.2019.100532.
Santin, A. D., Filiaci, V., Bellone, S., Ratner, E. S., Mathews, C. A., Cantuaria, G., Gunderson, C. C., Rutledge, T., Buttin, B. M., Lankes, H. A., Frumovitz, M., Khleif, S. N., Huh, W. K., & Birrer, M. J. (2020). Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). Gynecologic oncology reports, 31100532. https://doi.org/10.1016/j.gore.2019.100532
Santin, Alessandro D, et al. "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)." Gynecologic oncology reports vol. 31 (2020): 100532. doi: https://doi.org/10.1016/j.gore.2019.100532
Santin AD, Filiaci V, Bellone S, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Frumovitz M, Khleif SN, Huh WK, Birrer MJ. Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). Gynecol Oncol Rep. 2020 Jan 02;31:100532. doi: 10.1016/j.gore.2019.100532. eCollection 2020 Feb. PMID: 31934607; PMCID: PMC6951478.
Copy Download .nbib Format: NLM
Development and Evaluation of an Accelerometer-Based Protocol for Measuring Physical Activity Levels in Cancer Survivors: Development and Usability Study.

JMIR mHealth and uHealth

Crane TE, Skiba MB, Miller A, Garcia DO, Thomson CA.
PMID: 32969828
JMIR Mhealth Uhealth. 2020 Sep 24;8(9):e18491. doi: 10.2196/18491.

BACKGROUND: The collection of self-reported physical activity using validated questionnaires has known bias and measurement error.OBJECTIVE: Accelerometry, an objective measure of daily activity, increases the rigor and accuracy of physical activity measurements. Here, we describe the methodology and related...

Cite
Crane TE, Skiba MB, Miller A, et al. Development and Evaluation of an Accelerometer-Based Protocol for Measuring Physical Activity Levels in Cancer Survivors: Development and Usability Study. JMIR Mhealth Uhealth. 2020;8(9):e18491doi: 10.2196/18491.
Crane, T. E., Skiba, M. B., Miller, A., Garcia, D. O., & Thomson, C. A. (2020). Development and Evaluation of an Accelerometer-Based Protocol for Measuring Physical Activity Levels in Cancer Survivors: Development and Usability Study. JMIR mHealth and uHealth, 8(9), e18491. https://doi.org/10.2196/18491
Crane, Tracy E, et al. "Development and Evaluation of an Accelerometer-Based Protocol for Measuring Physical Activity Levels in Cancer Survivors: Development and Usability Study." JMIR mHealth and uHealth vol. 8,9 (2020): e18491. doi: https://doi.org/10.2196/18491
Crane TE, Skiba MB, Miller A, Garcia DO, Thomson CA. Development and Evaluation of an Accelerometer-Based Protocol for Measuring Physical Activity Levels in Cancer Survivors: Development and Usability Study. JMIR Mhealth Uhealth. 2020 Sep 24;8(9):e18491. doi: 10.2196/18491. PMID: 32969828; PMCID: PMC7545325.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries